Detalles de la búsqueda
1.
A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours.
Br J Cancer
; 128(8): 1418-1428, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36797356
2.
A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer.
Br J Cancer
; 129(10): 1608-1618, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37731023
3.
First-in-human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignancies.
Invest New Drugs
; 39(4): 1047-1056, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33594602
4.
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
Lancet Oncol
; 20(9): 1306-1315, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31378459
5.
Is there a role for combined anti-PD-1/CTLA-4 checkpoint blockade in the management of advanced biliary tract cancers?
Cancer
; 129(7): 1129-1130, 2023 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36692958
6.
A phase IIa study of HA-irinotecan, formulation of hyaluronic acid and irinotecan targeting CD44 in extensive-stage small cell lung cancer.
Invest New Drugs
; 36(2): 288-298, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29277856
7.
A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors.
Invest New Drugs
; 36(6): 1060-1071, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29980894
8.
A gut microbial signature for combination immune checkpoint blockade across cancer types.
Nat Med
; 30(3): 797-809, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38429524
9.
A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study.
Clin Cancer Res
; 29(6): 1017-1030, 2023 03 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-36638198
10.
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study.
J Thorac Oncol
; 18(2): 181-193, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36307040
11.
A tailored approach to horizon scanning for cancer medicines.
J Cancer Policy
; 38: 100441, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38008488
12.
Recruitment, outcomes, and toxicity trends in phase I oncology trials: Six-year experience in a large institution.
Cancer Rep (Hoboken)
; 5(2): e1465, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34245134
13.
Leveraging Comprehensive Cancer Registry Data to Enable a Broad Range of Research, Audit and Patient Support Activities.
Cancers (Basel)
; 14(17)2022 Aug 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-36077668
14.
Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors.
Clin Cancer Res
; 28(1): 95-105, 2022 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34615718
15.
BMS-986012, an Anti-Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study.
JTO Clin Res Rep
; 3(11): 100400, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36275912
16.
Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial.
J Immunother Cancer
; 9(11)2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34782426
17.
Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC.
Clin Lung Cancer
; 22(3): e425-e430, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32778511
18.
Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538.
Oncoimmunology
; 10(1): 1908771, 2021 04 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33889439
19.
Duration of dexamethasone administration for the prevention of chemotherapy-induced nausea and vomiting - A systematic review and meta-analysis.
Crit Rev Oncol Hematol
; 152: 103012, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-32593142
20.
Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial.
JAMA Oncol
; 6(9): 1405-1409, 2020 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32729929